Sofinnova Crossover I cuts Abivax voting rights stake below 5% to 4.92%

Sofinnova Partners, via Sofinnova Crossover I, reduced its voting rights stake in Abivax to 4.92% on July 1, 2026. The fund held 4,042,233 voting rights (4.92%) and 2,877,494 shares (3.61% of capital). This reduction followed an increase in total shares and voting rights combined with market sales.

Sofinnova Partners, managing Sofinnova Crossover I, cut its Abivax voting rights stake below 5% on July 1, 2026. * The fund held 2,877,494 shares, equal to 3.61% of capital, representing 4,042,233 voting rights, or 4.92%. * The drop followed a rise in total shares and voting rights, combined with market sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

ABVX